Caroline Samp advises private companies on a wide range of corporate matters, including formation, financings, mergers and acquisitions, and general corporate governance. Caroline also advises public companies with respect to ongoing annual and periodic reporting requirements, Section 16 matters, annual and special stockholder meetings, and Rule 144 compliance and related requests for stock certificate removal.
Boston University School of Law, J.D., cum laude, 2015
Mount Allison University, B.A., with Distinction, 2009
Bar and Court Admissions
BAR ADMISSIONS
Massachusetts
Experience
Enanta Pharmaceuticals, Inc. (Nasdaq: ENTA), a clinical-stage biotechnology company, on its $74.8 million public offering, which included the underwriters’ full exercise of their option to purchase additional shares
Ascend Wellness Holdings, Inc. (CSE: AAWH.U, OTCQX: AAWH), a leading multi-state, vertically integrated cannabis operator, in closing on a $50 million private placement of senior secured notes, issued at 97.5% of face value, and a supplemental part of a $235 million debt offering commenced in July and carry an interest rate of 12.75%
Butterfly Network, Inc. (NYSE: BFLY), a digital health company, on its $86.9 million public offering of its Class A common stock
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company, in its $130 million PIPE of Series A Convertible Preferred Stock
Zapata AI, an industrial Generative AI software company on the completion of its business combination with Andretti Acquisition Corp. (NYSE: WNNR), a special purpose acquisition company, which resulted in publicly traded combined company (Nasdaq: ZPTA and ZPTAW)
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases, in its sale to Syncona Limited (LON: SYNC) for approximately $23.5 million in cash ($0.34 per share)
Entegris, Inc. (Nasdaq: ENTG) in the acquisition of MPD Chemicals for approximately $16 million
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) in its acquisition of Syntimmune
Thermo Fisher Scientific Inc. (NYSE: TMO) in its acquisition of Becton, Dickinson and Company’s Advanced Bioprocessing business
Applied Genetic Technologies Corporation (Nasdaq: AGTC) in its sales agreement with Cantor Fitzgerald & Co. for an up to $25 million ATM offering
Zosano Pharma Corporation (Nasdaq: ZSAN):
$50 million underwritten public offering of common stock
$29.3 million underwritten public offering of common stock
Acer Therapeutics in its merger with Opexa Therapeutics
Nelson Properties Limited, a portfolio company managed by Global Forest Partners LP, in the sale of its subsidiary, Nelson Forests Limited, one of New Zealand's leading forestry businesses, to Australian forestry company OneFortyOne Plantations
Dell EMC in the sale of EMC’s enterprise content division to Open Text Corporation (Nasdaq: OTEX) (TSX: OTC) for $1.62 billion
Honors & Involvement
HONORS
Best Lawyers: Ones to Watch - Securities/Capital Markets Law (2024-2027), Mergers and Acquisitions Law (2023-2027), and Corporate Law (2026-2027)
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
